Modulation at multiple anchor positions of the peptide specificity of HLA-B27 subtypes differentially associated with ankylosing spondylitis

Arthritis and Rheumatism

Volumn 42, Issue 9, 1999, Pages 1975-1985

  Lamas, José R ^a   Paradela, Alberto ^a   Roncal, Fernando ^b   López De Castro, José A ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B27 ANTIGEN;

AMINO ACID COMPOSITION; ANIMAL CELL; ANKYLOSING SPONDYLITIS; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; GENETIC POLYMORPHISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

AMINO ACID SEQUENCE; EPITOPES; HLA-B27 ANTIGEN; HUMANS; LIGANDS; PEPTIDES; POLYMORPHISM, GENETIC; SPONDYLITIS, ANKYLOSING;

EID: 0033495770     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199909)42:9<1975::AID-ANR25>3.0.CO;2-V     Document Type: Article

References (47)

1. Madden DR. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol 1995;13:587-622.
2. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995;41:178-228.
3. Ruppert J, Sidney J, Cells E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993;74:929-37.
4. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet 1973; 1:904-7.
5. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 1973;288:704-6.
6. Kingsley G, Sieper J. Current perspectives in reactive arthritis. Immunol Today 1993;14:387-91.
7. Benjamin R, Parham P. Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today 1990;11:137-42.
8. Zhou M, Sayad A, Simmons WA, Jones RC, Maika SD, Satumtira N, et al. The specificity of peptides bound to human histocompatihility leukocyte antigen (HLA)-B27 influences the prevalence of arthritis in HLA-B27 transgenic rats. J Exp Med 1998;188:877-86.
9. Breur-Vriesendorp BS, Dekker Saeys AJ, Ivanyi P. Distribution of HLA-B27 subtypes in patients with ankylosing spondylitis: the disease is associated with a common determinant of the various B27 molecules. Ann Rheum Dis 1987;46:353-6.
10. D'Amato M, Fiorillo MT, Carcassi C, Mathieu A, Zuccarelli A, Bitti PP, et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol 1995; 25:3199-201.
11. Lopez-Larrea C, Sujirachato K, Mehra NK, Chiewsilp P, Isarangkura D, Kanga U, et al. HLA-B27 subtypes in Asian patients with ankylosing spondylitis: evidence for new associations. Tissue Antigens 1995;45:169-76.
12. Nasution AR, Mardjuadi A, Kunmartini S, Suryadhana NG, Setyohadi B, Sudarsono D, et al. HLA-B27 subtypes positively and negatively associated with spondyloarthropathy. J Rheumatol 1997;24:1111-4.
13. Ren EC, Koh WH, Sim D, Boey ML, Wee GB, Chan SH. Possible protective role of HLA-B*2706 for ankylosing spondylitis. Tissue Antigens 1997;49:67-9.
14. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC. Identification of self peptides bound to purified HLA-B27. Nature 1991;353:326-9.
15. Madden DR, Gorga JC, Strominger JL, Wiley DC. The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC. Cell 1992;70:1035-48.
16. Rotzschke O, Falk K, Stevanovic S, Gnau V, Jung G, Rammensee HG. Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and B*2705 peptide motifs. Immunogenetics 1994;39: 74-7.
17. Boisgérault F, Tieng V, Stolzenberg MC, Dulphy N, Khalil I, Tamouza R, et al. Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants: implications for susceptibility to spondylarthropathies. J Clin Invest 1996;98: 2764-70.
18. Griffin TA, Yuan J, Friede T, Stevanovic S, Ariyoshi K, Rowland-Jones SL, et al. Naturally occurring A pocket polymorphism in HLA-B*2703 increases the dependence on an accessory anchor residue at P1 for optimal binding of nonamer peptides. J Immunol 1997;159:4887-97.
19. Garcia F, Rognan D, Lamas JR, Marina A, Lopez de Castro JA. An HLA-B27 polymorphism (B*2710) that is critical for T-cell recognition has limited effects on peptide specificity. Tissue Antigens 1998;58:1-9.
20. Garcia F, Galocha B, Villadangos JA, Lamas JR, Alhar JP, Marina A, et al. HLA-B27 (B*2701) specificity for peptides lacking Arg2 is determined by polymorphism outside the B pocket. Tissue Antigens 1997;49:580-7.
21. Garcia F, Marina A, Lopez de Castro JA. Lack of carboxyl-terminal tyrosine distinguishes the B*2706-bound peptide repertoire from those of B*2704 and other HLA-B27 subtypes associated to ankylosing spondylitis. Tissue Antigens 1997;49:215-21.
22. Tieng V, Dulphy N, Boisgérault F, Tamouza R, Charron D, Toubert A. HLA-B*2707 peptide motif: Tyr C-terminal anchor is not shared by all disease-associated subtypes. Immunogenetics 1997;47:103-5.
23. Fiorillo MT, Meadows L, D'Amato M, Shabanowitz J, Hunt DF, Apella E, et al. Susceptibility to ankylosing spondylitis correlates with the C-terminal residue of peptides presented by various HLA-B27 subtypes. Eur J Immunol 1997;27:368-73.
24. Rovero P, Riganelli D, Fruci D, Vigano S, Pegoraro S, Revoltella R, et al. The importance of secondary anchor residue motifs of HLA class I proteins: a chemometric approach. Mol Immunol 1994;31:549-54.
25. Fruci D, Greco G, Vigneti E, Tanigaki N, Butler RH, Tosi R. The peptide-binding specificity of HLA-B27 subtype (B*2705) analyzed by the use of polyalanine model peptides. Hum Immunol 1994;41:34-8.
26. Wen J, Wang J, Kuipers JG, Huang F, Williams KM, Raybourne RB, et al. Analysis of HLA-B*2705 peptide motif, using T2 cells and monoclonal antibody ME1. Immunogenetics 1994;39:444-6.
27. Colbert RA, Rowland Jones SL, McMichael AJ, Frelinger JA. Differences in peptide presentation between B27 subtypes: the importance of the P1 side chain in maintaining high affinity peptide binding to B*2703. Immunity 1994;1:121-30.
28. Villadangos JA, Galocha B, Garcia F, Albar JP, Lopez de Castro JA. Modulation of peptide binding by HLA-B27 polymorphism in pockets A and B, and peptide specificity of B*2703. Eur J Immunol 1995;25:2370-7.
29. Ljunggren HG, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants: analysis of the mechanism. J Exp Med 1985;162:1745-59.
30. Townsend A, Ohlen C, Bastin J. Ljunggren HG, Foster L, Karre K. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 1989;340:443-8.
31. Ljunggren HG, Stam NJ, Ohlen C, Neefjes JJ, Hoglund P, Heemels MT, et al. Empty MHC class I molecules come out in the cold. Nature 1990;346:476-80.
32. Galocha B, Lamas JR, Villadangos JA, Albar JP, Lopez de Castro JA. Binding of peptides naturally presented by HLA-B27 to the differentially disease-associated B*2704 and B*2706 subtypes, and to mutants mimicking their polymorphism. Tissue Antigens 1996; 48:509-18.
33. Villadangos JA, Galocha B, Lopez de Castro JA. Unusual topology of an HLA-B27 allospecific T cell epitope lacking peptide specificity. J Immunol 1994;152:2317-23.
34. Ellis SA, Taylor C, McMichael A. Recognition of HLA-B27 and related antigens by a monoclonal antibody. Hum Immunol 1982; 5:49-59.
35. Paradela A, Garcia-Peydro M, Vazquez J, Rognan D, Lopez de Castro JA. The same natural ligand is involved in allorecognition of multiple HLA-B27 subtypes by a single T cell clone: role of peptide and the MHC molecule in alloreactivity. J Immunol 1998;161:5481-90.
36. Yague J, Vazquez J, Lopez de Castro JA. A single amino acid change makes the peptide specificity of B*3910 unrelated to B*3901 and closer to a group of HLA-B proteins including the malaria-protecting allotype HLA-B53. Tissue Antigens 1998;52:416-21.
37. Barber LD, Percival L, Parham P. Characterization of the peptide-binding specificity of HLA-B*7301. Tissue Antigens 1996;47:472-7.
38. Van Enden PM, Riganelli D, Greco G, Fleischhauer K, Sidney J, Sette A, et al. The peptide-binding motif for the human transporter associated with antigen processing. J Exp Med 1995;182: 1883-95.
39. Uebel S, Kraas W, Kienle S, Wiesmuller KH, Jung G, Tampe R. Recognition principle of the TAP transporter disclosed by combinatorial peptide libraries. Proc Natl Acad Sci U S A 1997;94:8976-81.
40. Daniel S, Brusic V, Caillat-Zucman S, Petrovsky N, Harrison L, Riganelli D, et al. Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules. J Immunol 1998;161:617-24.
41. Peh CA, Burrows SR, Barnden M, Khanna R. Cresswell P, Moss DJ, et al. HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. Immunity 1998;8:531-42.
42. Rognan D, Scapozza L, Folkers G, Daser A. Rational design of nonnatural peptides as high-affinity ligands for the HLA-B*2705 human leukocyte antigen. Proc Natl Acad Sci U S A 1995;92: 753-7.
43. Krebs S, Lamas JR, Poenaru S, Folkers G, Lopez de Castro JA, Seebach D, et al. Substituting nonpeptidic spacers for the T cell receptor-binding part of class I major histocompatibility complex-binding peptides. J Biol Chem 1998;273:19072-9.
44. Brooks JM, Murray RJ, Thomas WA, Kurilla MG, Rickinson AB. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J Exp Med 1993;178:879-87.
45. Van Binnendijk RS, Versteeg-van Oosten JP, Poelen MC, Brugghe HF, Hoogerhout P, Osterhaus AD, et al. Human HLA class I- and HLA class II-restricted cloned cytotoxic T lymphocytes identify a cluster of epitopes on the measles virus fusion protein. J Virol 1993;67:2276-84.
46. Ugrinovic S, Mertz A, Wu P, Braun J, Sieper J. A single nonamer from the Yersinia 60Kd heat shock protein is the target of HLA-B27 restricted CTL response in Yersinia-induced reactive arthritis. J Immunol 1997;159:5715-23.
47. Garcia F, Marina A, Albar JP, Lopez de Castro JA. HLA-B27 presents a peptide from a polymorphic region of its own molecule with homology to proteins from arthritogenic bacteria. Tissue Antigens 1997;49:23-8.